(Q44740671)

English

Epidermal growth factor receptor R521K polymorphism shows favorable outcomes in KRAS wild-type colorectal cancer patients treated with cetuximab-based chemotherapy

scientific article published on 22 February 2012

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

Epidermal growth factor receptor R521K polymorphism shows favorable outcomes in KRAS wild-type colorectal cancer patients treated with cetuximab-based chemotherapy (English)

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

colorectal cancer

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

colorectal carcinoma

1 reference

based on heuristic

inferred from title

author name string

Yao-Yu Hsieh

1

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

Cheng-Hwai Tzeng

2

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

Ming-Huang Chen

3

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

Po-Min Chen

4

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

Wei-Shu Wang

5

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

publication date

22 February 2012

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

103

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

4

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

791-796

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

Cetuximab (Erbitux)--an emerging targeted therapy for epidermal growth factor receptor-expressing tumours

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2012.02225.X

21 January 2018

Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2012.02225.X

21 January 2018

Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2012.02225.X

21 January 2018

A polymorphism of EGFR extracellular domain is associated with progression free-survival in metastatic colorectal cancer patients receiving cetuximab-based treatment

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2012.02225.X

21 January 2018

PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2012.02225.X

21 January 2018

KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2012.02225.X

21 January 2018

Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2012.02225.X

21 January 2018

The importance of KRAS mutations and EGF61A>G polymorphism to the effect of cetuximab and irinotecan in metastatic colorectal cancer.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2012.02225.X

21 January 2018

Correlation of FCGR3A and EGFR germline polymorphisms with the efficacy of cetuximab in KRAS wild-type metastatic colorectal cancer.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2012.02225.X

21 January 2018

Gene polymorphisms of epidermal growth factor receptor and its downstream effector, interleukin-8, predict oxaliplatin efficacy in patients with advanced colorectal cancer

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2012.02225.X

21 January 2018

A variant epidermal growth factor receptor exhibits altered type alpha transforming growth factor binding and transmembrane signaling

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2012.02225.X

21 January 2018

Genetic polymorphisms in the EGFR (R521K) and estrogen receptor (T594T) genes, EGFR and ErbB-2 protein expression, and breast cancer risk in Tunisia

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2012.02225.X

21 January 2018

Polymorphisms in cyclooxygenase-2 and epidermal growth factor receptor are associated with progression-free survival independent of K-ras in metastatic colorectal cancer patients treated with single-agent cetuximab

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2012.02225.X

21 January 2018

Polymorphisms of EGFR predict clinical outcome in advanced non-small-cell lung cancer patients treated with Gefitinib.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2012.02225.X

21 January 2018

ERCC1 codon 118 C→T polymorphism associated with ERCC1 expression and outcome of FOLFOX-4 treatment in Asian patients with metastatic colorectal carcinoma

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2012.02225.X

21 January 2018

Very low prevalence of XPD K751Q polymorphism and its association with XPD expression and outcomes of FOLFOX-4 treatment in Asian patients with colorectal carcinoma

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2012.02225.X

21 January 2018

The role of the EGFR signaling in tumor microenvironment.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2012.02225.X

21 January 2018

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2012.02225.X

21 January 2018

Somatic mutations of EGFR in colorectal cancers and glioblastomas

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2012.02225.X

21 January 2018

A phase II randomized multicenter trial of gefitinib plus FOLFIRI and FOLFIRI alone in patients with metastatic colorectal cancer.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2012.02225.X

21 January 2018

Molecular study of malignant gliomas treated with epidermal growth factor receptor inhibitors: tissue analysis from North American Brain Tumor Consortium Trials 01-03 and 00-01.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2012.02225.X

21 January 2018

Structural basis for inhibition of the epidermal growth factor receptor by cetuximab

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2012.02225.X

21 January 2018

Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2012.02225.X

21 January 2018

Vascular endothelial growth factor: its prognostic, predictive, and therapeutic implications

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2012.02225.X

21 January 2018

Activated VEGFR2/KDR pathway in tumour cells and tumour associated vessels of colorectal cancer

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2012.02225.X

21 January 2018

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2012.02225.X

21 January 2018

UGT1A1*28 polymorphism predicts irinotecan-induced severe toxicities without affecting treatment outcome and survival in patients with metastatic colorectal carcinoma

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2012.02225.X

21 January 2018

Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2012.02225.X

21 January 2018

Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2012.02225.X

21 January 2018

Multiple K-ras codon 12 mutations in cholangiocarcinomas demonstrated with a sensitive polymerase chain reaction technique.

1 reference

https://pubmed.ncbi.nlm.nih.gov/22321154

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Expression and function of vascular endothelial growth factor receptor-1 on human colorectal cancer cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/22321154

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Gefitinib (IRESSA) in patients of Asian origin with refractory advanced non-small cell lung cancer: subset analysis from the ISEL study

1 reference

https://pubmed.ncbi.nlm.nih.gov/22321154

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Epidermal growth factor receptor R497K polymorphism is a favorable prognostic factor for patients with colorectal carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/22321154

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Functional Analysis and DNA Polymorphism of the Tandemly Repeated Sequences in the 5'-terminal Regulatory Region of the Human Gene for Thymidylate Synthase

1 reference

https://pubmed.ncbi.nlm.nih.gov/22321154

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab

1 reference

https://pubmed.ncbi.nlm.nih.gov/22321154

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Epidermal growth factor receptor gene polymorphisms predict pelvic recurrence in patients with rectal cancer treated with chemoradiation.

1 reference

https://pubmed.ncbi.nlm.nih.gov/22321154

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1111/J.1349-7006.2012.02225.X

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

PMC publication ID

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44740671&oldid=2036441495"